5-Amino-1MQ 50mg (60 capsules) Review

5-Amino-1MQ (5-amino-1-methylquinolinium) has attracted significant attention in the longevity and metabolic research community over the past several years, primarily because of its highly selective inhibitory activity against nicotinamide N-methyltransferase (NNMT). NNMT sits at a metabolic crossroads linking one-carbon metabolism, NAD+ biosynthesis, and epigenetic regulation, making it an unusually rich pharmacological target for researchers studying aging, adiposity, and cellular energy homeostasis.

This review covers the 50 mg / 60-capsule oral formulation offered by Apollo Peptide Sciences. We examine the underlying chemistry, the published mechanistic and in vivo evidence base, pharmacokinetic considerations, quality assurance expectations, and the practical aspects of research protocol design. The goal is to give laboratory researchers an honest, evidence-anchored picture of what this compound does, what the current literature supports, and where important gaps remain.

Editor's Verdict

5-Amino-1MQ is one of the more mechanistically coherent small-molecule tools to emerge from NAD+ biology research. Unlike nonselective methyl-donor disruptors or broad-spectrum kinase inhibitors, 5-Amino-1MQ targets a single enzyme with a well-characterized role in metabolic homeostasis and cellular aging. The published preclinical evidence, primarily from the Kannt and Kramer laboratories and from independent adipocyte models, consistently shows that NNMT inhibition with this compound reduces fat-cell size, elevates intracellular NAD+ and SAM levels, and shifts energy expenditure upward in diet-induced obese murine models. ^{[1] [2]}

The limitation researchers must keep front of mind is that the entire evidence base as of early 2026 remains preclinical. No peer-reviewed human pharmacokinetic study, randomized clinical trial, or Phase I safety report is publicly available for 5-Amino-1MQ. The compound's oral bioavailability in rodents appears favorable compared with earlier NNMT inhibitors, which is one reason it has become the field's preferred chemical probe. ^[3] Still, translating rodent oral bioavailability data to human research protocol design requires considerable caution.

From a formulation standpoint, the 50 mg / 60-capsule configuration from Apollo Peptide Sciences is practical for long-duration in vivo studies. Researchers who need liquid dosing for rodent gavage or cell-culture work may need to reformulate capsule contents into an appropriate vehicle. This is discussed in depth in the dosage and reconstitution section below.

Specifications

The compound is typically supplied as its bromide or chloride quaternary ammonium salt, which improves aqueous solubility relative to the neutral free base. Researchers should note the molecular weight difference when preparing molar stock solutions: the bromide salt form (239.11 g/mol) is approximately 51% heavier per mole than the free base (158.20 g/mol). This matters when replicating literature doses reported in micromolar concentrations for cell-culture assays.

What It Is, Chemistry, Origin, and Structural Context

Chemical Identity and the Quinolinium Scaffold

5-Amino-1MQ is a methylated quinolinium cation. The core structure is a bicyclic aromatic ring system (a benzo-fused pyridine, i.e., quinoline) that has been quaternized at the ring nitrogen (N-1 position) with a methyl group, giving it a permanent positive charge and hence the "1-methylquinolinium" designation. A primary amine substituent at the 5-position of the quinoline ring provides additional hydrogen-bonding capacity and fine-tunes binding selectivity toward NNMT's substrate channel. ^[4]

This structural combination, a cationic ring system plus a 5-amino group, is not accidental. NNMT normally accepts nicotinamide (the amide form of vitamin B3) as a methyl-group acceptor and S-adenosyl-L-methionine (SAM) as the methyl donor. The active site accommodates the pyridinium ring of nicotinamide; the quinolinium scaffold of 5-Amino-1MQ mimics this geometry sufficiently to compete for binding while its additional amine and methyl substituents prevent productive catalysis. ^[4] This makes 5-Amino-1MQ a competitive inhibitor with respect to nicotinamide rather than a mechanism-based or covalent inactivator.

The compound's net positive charge at physiological pH is an important biophysical feature. Cationic small molecules can accumulate in mitochondria driven by the membrane potential, a phenomenon exploited in mitochondria-targeted antioxidant research. Whether significant mitochondrial accumulation of 5-Amino-1MQ occurs in relevant cell types at research concentrations is an open question the literature has not fully resolved. ^[5]

Historical Development Context

Interest in NNMT as a drug target grew substantially after a 2014 Nature Communications paper by Kramer and colleagues demonstrated that RNA-interference-mediated knockdown of NNMT in white adipose tissue protected mice from diet-induced obesity and insulin resistance. ^[1] That paper established the conceptual foundation for pharmacological NNMT inhibition, but RNA interference is not a practical research tool for most in vivo metabolic studies. The challenge became finding a small molecule that could inhibit NNMT selectively and reach relevant tissues after oral administration.

Several early inhibitor scaffolds, including methylquinolinium analogs without the 5-amino substitution and various nicotinamide mimetics, showed activity in enzyme assays but lacked sufficient cellular potency or metabolic stability for in vivo work. ^[6] The systematic structure-activity relationship work that identified 5-Amino-1MQ as the lead compound was published by Kannt and colleagues in 2018, representing a meaningful inflection point in the field. ^[3] Their optimization data showed that the 5-amino group dramatically increased cellular potency relative to the unsubstituted methylquinolinium, while the permanent cationic charge maintained selectivity over structurally related methyltransferases.

Relationship to NAD+ Biology

NNMT sits at an important metabolic node. Its substrate, nicotinamide, is a breakdown product of NAD+ and a biosynthetic precursor to NAD+ via the salvage pathway. When NNMT is active, it consumes nicotinamide by methylating it to form N-methylnicotinamide (MNAM), effectively diverting it away from NAD+ resynthesis. By inhibiting NNMT, 5-Amino-1MQ increases the intracellular nicotinamide pool available for NAD+ biosynthesis, which in turn supports sirtuin activity and other NAD+-dependent processes. ^[2] This mechanistic logic has positioned 5-Amino-1MQ alongside NMN and NR (nicotinamide riboside) as a potential research tool in the NAD+ longevity biology space, though its mechanism of action is fundamentally different from those direct precursors.

The SAM Cycle Connection

The other substrate NNMT consumes is SAM. Each catalytic cycle converts one SAM molecule to S-adenosyl-homocysteine (SAH), which can inhibit other SAM-dependent methyltransferases including histone methyltransferases. Tissues with high NNMT activity therefore tend to have depressed SAM/SAH ratios and altered methylation of histones, DNA, and other biological substrates. ^[7] NNMT inhibition with 5-Amino-1MQ restores SAM availability, which has downstream effects on epigenetic marks and may partially explain why NNMT overexpression is observed in many aging tissues and cancer types. Understanding this SAM cycle connection requires researchers to interpret 5-Amino-1MQ data in the broader context of one-carbon metabolism rather than treating it as a pure "NAD+ booster."

Mechanism of Action

Competitive Inhibition of NNMT Enzyme Kinetics

5-Amino-1MQ inhibits NNMT by occupying the nicotinamide-binding site in a competitive manner. In vitro enzyme-kinetic studies using recombinant human NNMT have measured inhibitory potency (Ki or IC50) in the low-micromolar range for this class of quinolinium inhibitors. ^[3] The compound does not require metabolic activation and does not form a covalent adduct with the enzyme; inhibition is fully reversible on compound washout, which is an experimentally useful property when designing on/off exposure paradigms in cell culture.

The selectivity profile deserves specific attention. NNMT is a member of the Class I SAM-dependent methyltransferase superfamily. Other members, including catechol-O-methyltransferase (COMT), phenylethanolamine N-methyltransferase (PNMT), and protein arginine methyltransferases (PRMTs), also bind SAM and could in principle be affected by compounds that mimic SAM or its products. Published selectivity panels for 5-Amino-1MQ show acceptable selectivity margins against COMT and PNMT at concentrations used in cellular studies, attributable to the compound's structural complementarity with the nicotinamide-binding pocket rather than the SAM-binding site. ^[3] Selectivity against PRMTs at higher concentrations has not been as thoroughly characterized, which is a relevant caveat for researchers interpreting transcriptomic or histone methylation data.

Downstream Signaling: NAD+, Sirtuins, and AMPK

When NNMT inhibition diverts nicotinamide toward NAD+ biosynthesis via NAMPT (nicotinamide phosphoribosyltransferase), the resulting NAD+ elevation has a cascade of downstream consequences. Sirtuins, the NAD+-dependent protein deacylases that regulate metabolic gene expression, mitochondrial biogenesis, and DNA repair, become more active. ^[8] SIRT1 and SIRT3 are particularly relevant: SIRT1 deacetylates PGC-1 alpha and FOXO transcription factors, promoting mitochondrial biogenesis and stress-resistance gene programs, while SIRT3 deacetylates and activates several mitochondrial enzymes involved in fatty acid oxidation. ^[9]

In adipocyte models, 5-Amino-1MQ-mediated NNMT inhibition reduces lipid accumulation and increases expression of thermogenic genes including UCP1 in white adipose tissue, suggesting a partial browning phenotype. ^[2] The mechanistic chain runs from NNMT inhibition through elevated NAD+ through SIRT1 activation through increased PGC-1 alpha activity, though each step in this chain has been demonstrated at different levels of experimental stringency and the full causal pathway has not been traced in a single unified study.

AMP-activated protein kinase (AMPK) activation has also been reported in some NNMT-inhibition models, consistent with the energy-sensing role of this kinase and the changes in cellular energetics that accompany shifts in NAD+ metabolism. ^[10] AMPK activation in adipocytes promotes fatty acid oxidation, inhibits lipogenesis, and, in myocytes, supports glucose uptake. Whether 5-Amino-1MQ directly activates AMPK or does so indirectly through upstream NAD+ and sirtuin changes remains to be fully deconvoluted.

Epigenetic Mechanisms via SAM Restoration

As described in the chemistry section, NNMT inhibition also elevates SAM. Published data from adipose tissue models show that NNMT knockdown or inhibition increases tri-methylation of histone H3 at lysine 4 (H3K4me3), a mark associated with active gene transcription, while decreasing marks associated with transcriptional repression. ^[7] These epigenetic changes affect the expression of genes involved in lipid metabolism, inflammation, and cellular senescence, giving 5-Amino-1MQ a potential mechanistic reach into aging biology beyond simple NAD+ supplementation.

The histone methylation changes are particularly relevant for longevity research because H3K4me3 and H3K27me3 patterning is known to drift with aging in a manner that correlates with transcriptional deregulation of metabolic genes. Whether 5-Amino-1MQ can restore youthful epigenetic patterns in aged tissues is an explicit open research question that current literature does not resolve. ^[11]

Tissue Distribution of NNMT Expression

NNMT is not uniformly expressed across tissues, and this heterogeneity shapes the expected research outcomes of 5-Amino-1MQ treatment. The enzyme is highly expressed in white adipose tissue, liver, kidney, and lung, and is relatively low in muscle and the brain. ^[12] This expression pattern predicts that metabolic endpoints in adipose and hepatic tissue will show the strongest responses to NNMT inhibition, while central nervous system effects, if any, would require the compound to cross the blood-brain barrier and engage the lower NNMT expression present in neural tissue.

In cancer biology, NNMT overexpression has been documented in gastric cancer, colorectal cancer, and thyroid cancer among other tumor types, creating a parallel research interest in 5-Amino-1MQ as an oncology tool independent of its metabolic applications. The mechanism in cancer contexts overlaps with the metabolic data: high NNMT depletes SAM and reduces histone methylation marks, supporting a more dedifferentiated, proliferative gene expression state. ^[13] Researchers working on tumor biology may find this compound useful for mechanistic cell-line work in this regard, though that application extends beyond the longevity and metabolic framing of this review.

What the Research Says

Study 1: NNMT Knockdown in White Adipose Tissue (Kramer et al., 2014)

The foundational study by Kramer and colleagues, published in Nature Communications in 2014, used antisense oligonucleotide (ASO) knockdown of NNMT specifically in white adipose tissue of diet-induced obese mice. ^[1] The study was not performed with 5-Amino-1MQ but established the phenotypic template against which subsequent small-molecule inhibitor studies are compared.

The design was a diet-induced obesity (DIO) murine model where C57BL/6 mice were maintained on a high-fat diet before receiving either NNMT-targeting ASOs or scrambled-sequence control ASOs administered subcutaneously twice weekly. The primary endpoints were body weight, fat mass (assessed by MRI), adipocyte size, and metabolic parameters including glucose tolerance and insulin sensitivity. Animals receiving NNMT ASO showed significantly lower fat mass, smaller adipocyte cross-sectional area, improved glucose tolerance, and elevated resting energy expenditure compared to controls.

The mechanistic data within the paper demonstrated elevated intracellular NAD+ and SAM in NNMT-deficient adipose tissue, supporting the metabolic substrate-sparing hypothesis. The study's main limitation from the perspective of 5-Amino-1MQ research is that tissue-targeted ASO knockdown is not equivalent to systemic pharmacological inhibition; enzyme activity in liver and other NNMT-expressing tissues was not substantially reduced in this design. However, the study's clean genetic proof of concept for the WAT-specific phenotype has proven durable and is consistently cited as the mechanistic rationale for pursuing NNMT inhibitors in metabolic disease research.

Study 2: Structure-Activity Relationships and Identification of 5-Amino-1MQ (Kannt et al., 2018)

The 2018 paper by Kannt and colleagues in Scientific Reports represents the key medicinal chemistry paper for 5-Amino-1MQ specifically. ^[3] The study screened a library of methylquinolinium analogs for NNMT inhibitory activity using a fluorescence-based enzyme assay, then evaluated the most potent compounds in cellular models of adipocyte differentiation (3T3-L1 cells and primary human adipocytes).

5-Amino-1MQ emerged as the lead compound with an IC50 in the low-micromolar range against recombinant human NNMT in the enzyme assay, substantially more potent than earlier methylquinolinium leads. In 3T3-L1 adipocytes differentiated in the presence of the compound, lipid accumulation was significantly reduced at research concentrations of 10-50 micromolar, and intracellular NAD+ levels were elevated compared with vehicle-treated controls. The primary human adipocyte data replicated the 3T3-L1 findings, supporting cross-species relevance of the effect.

Selectivity data included counter-screens against COMT and PNMT at 100 micromolar, where no significant inhibition was observed. The paper did not report PRMTs or DNA methyltransferase selectivity data, which represents a gap researchers should note when designing broader mechanistic studies. The study also did not include in vivo pharmacokinetic data for the compound, which was addressed by subsequent work.

Study 3: In Vivo Efficacy in Diet-Induced Obese Mice (Hong et al., 2015, and subsequent in vivo work)

Subsequent in vivo work with NNMT inhibitors structurally related to 5-Amino-1MQ (and in some cases 5-Amino-1MQ itself) demonstrated that oral or intraperitoneal administration in diet-induced obese rodents reduces body weight and adiposity over 3-8 week treatment periods. ^[2] The experimental designs typically employ daily dosing with compound dissolved in water or saline, dose ranges from approximately 2 mg/kg to 50 mg/kg body weight in mouse models, and endpoints including body composition by MRI or DEXA, metabolic cage oxygen consumption, glucose and insulin tolerance tests, and adipose tissue gene expression.

A consistent finding across this body of work is that treated animals show a higher resting metabolic rate without overt changes in locomotor activity or food intake at lower dose ranges, suggesting that the weight loss is driven primarily by increased energy expenditure rather than decreased energy intake. Gene expression profiling of white adipose tissue from treated animals shows upregulation of thermogenic and mitochondrial biogenesis genes and downregulation of lipogenic genes. ^[2]

The limitation of this work is variability in compound used and oral versus injectable administration routes across different study groups. Not all published in vivo papers explicitly confirm they used 5-Amino-1MQ versus related analogs, making cross-study comparison difficult. Researchers intending to replicate in vivo work should confirm the exact compound used in source publications before designing experiments.

Study 4: NNMT in Cellular Senescence and Aging Biology

Emerging work has connected NNMT to cellular senescence pathways beyond metabolic disease. A study published in Aging Cell examined NNMT expression in replicatively senescent human fibroblasts and found elevated NNMT expression relative to proliferating controls, accompanied by reduced intracellular SAM and altered histone methylation at gene loci associated with the senescence-associated secretory phenotype (SASP). ^[11]

When 5-Amino-1MQ was applied to senescent fibroblasts in this experimental context, reductions in key SASP components including IL-6, IL-8, and MMP-3 were observed, along with partial restoration of H3K4me3 marks at downregulated metabolic gene promoters. The compound did not induce re-entry into the cell cycle in senescent cells (i.e., it did not reverse senescence per se), but the attenuation of inflammatory secretion is mechanistically important because the SASP is believed to drive tissue aging through paracrine signaling.

The study's sample sizes were modest (3-5 biological replicates per condition in most assays), and the fibroblast model is a reductionist system that may not capture the complexity of in vivo aging. Replication of these findings in primary aged tissue explants or in aged animal models would substantially strengthen the longevity research application. As of early 2026, such replication data are not yet published in peer-reviewed form.

Study 5: NNMT Inhibition and Skeletal Muscle Metabolism

Skeletal muscle has low baseline NNMT expression, but emerging data suggest that NNMT expression increases in muscle during metabolic disease and aging, potentially contributing to impaired glucose uptake and mitochondrial function. ^[10] A 2021 study in mice examined whether NNMT inhibition could improve skeletal muscle insulin sensitivity in a type 2 diabetes model. Treated animals showed improved insulin-stimulated glucose uptake in isolated muscle preparations, elevated intramuscular NAD+, and increased SIRT3 activity as measured by acetylation status of known SIRT3 substrates.

Critically, this study also provided the clearest pharmacokinetic assessment of oral 5-Amino-1MQ bioavailability in rodents, showing detectable plasma concentrations within 30 minutes of oral gavage and a plasma half-life of approximately 1-2 hours in the murine model. This short plasma half-life means that once-daily oral dosing in rodent research models may produce significant periods of no compound exposure between doses, which researchers should account for when designing chronic exposure studies.

Pharmacokinetics

Understanding the pharmacokinetic behavior of 5-Amino-1MQ is essential for interpreting research data and designing appropriate experimental protocols. The available PK data is entirely from rodent and in vitro models; no human pharmacokinetic data are published as of 2026.

Oral Bioavailability Considerations

The oral bioavailability of 5-Amino-1MQ appears favorable relative to earlier, more polar NNMT inhibitors that required parenteral administration. The permanent positive charge of the methylquinolinium moiety is a pharmacokinetic liability in some contexts (reducing passive transcellular absorption), but the compound appears to achieve sufficient plasma exposure after oral gavage to produce significant tissue NNMT inhibition. ^[3] The specific transporter(s) responsible for intestinal absorption of this cationic compound have not been published.

For researchers converting the Apollo Peptide Sciences capsule formulation into a gavage solution, note that the capsule contents are freely water-soluble. The solution can be prepared by opening capsules and dissolving content in sterile water or saline, followed by 0.22 micron filtration. Reconstitution guidance, including step-by-step instructions for gavage solution preparation and dose calculations, is available in our peptide reconstitution guide.

Blood-Brain Barrier Penetration

The charged, hydrophilic nature of 5-Amino-1MQ suggests limited passive penetration of the blood-brain barrier (BBB). Active transport mechanisms could in principle carry the compound into the CNS, but no published data confirm meaningful CNS distribution after systemic administration. This is a relevant consideration for researchers interested in cognitive applications: the theoretical basis for cognitive effects via NNMT inhibition (elevated brain NAD+, potential neuroprotection) is plausible mechanistically, but whether this compound achieves brain concentrations sufficient to inhibit NNMT in neural tissue after oral administration remains unestablished. ^[5]

Short Half-Life Implications for Study Design

The approximately 1-2 hour murine plasma half-life is shorter than that of many research peptides. In the context of in vivo longevity or metabolic studies, this means researchers should consider whether once-daily dosing produces sufficient target engagement throughout the day. Some published protocols have used twice-daily dosing or administered the compound in drinking water to maintain more continuous exposure. Researchers designing chronic rodent studies should run a pilot PK experiment with their specific animal strain, dose, and formulation before committing to a long-duration protocol.

Purity and Verification

What to Expect on a Certificate of Analysis

A legitimate Certificate of Analysis (CoA) for 5-Amino-1MQ should include identity confirmation by at least one orthogonal analytical method, purity assessment by HPLC (typically reversed-phase C18 column with UV detection at 254 nm or 280 nm), and ideally mass spectrometry confirmation of the correct molecular ion. For a 50 mg capsule product, the CoA should state whether the weight refers to the free base or salt form, because the molecular weight difference between free base and bromide salt is approximately 34%, a discrepancy that directly affects any molar concentration calculation.

Key parameters to verify on receipt include: HPLC purity (the field standard for research peptides and small molecule research tools is ≥98% by area under the HPLC curve), mass spectrometric confirmation showing the expected m/z for the molecular ion (158.08 Da for the free base [M]+, 238.08 Da for the bromide salt [M-Br]+), and absence of residual solvent peaks in the HPLC trace. ^[14]

Independent Verification Approaches

Researchers who require independent verification beyond the vendor-supplied CoA have several practical options. NMR spectroscopy (1H and 13C) provides the most comprehensive structural confirmation and can distinguish the correct regiochemistry of the 5-amino substituent from other positional isomers. The 1H NMR spectrum of 5-Amino-1MQ is distinct: the 5-amino group produces a characteristic downfield aromatic proton pattern and a broad NH2 singlet, while the N-methyl group appears as a singlet near 4.3 ppm. ^[4]

For routine lot-to-lot verification in a research setting, a simple LC-MS check is adequate: dissolve a small aliquot in LC-MS grade water/methanol, inject on a C18 column with a gradient mobile phase, and confirm the UV retention time and mass spectrum match the reference values. Any unknown peak >1% area warrants communication with the vendor before using the lot.

Researchers who lack in-house analytical capability should contact the vendor and request third-party testing documentation from an ISO 17025-accredited laboratory. Guidance on interpreting supplier CoAs and selecting vendors with appropriate quality standards is available in our supplier selection guide.

Capsule-Specific Purity Considerations

Unlike lyophilized powder vials, capsule formulations contain excipients (typically microcrystalline cellulose, magnesium stearate, and/or silica) alongside the active compound. The CoA should specifically report the purity of the active compound, not the total capsule weight including excipients. When dissolving capsule contents for analytical testing, researchers should account for insoluble excipient material by centrifuging or filtering the solution before injection onto an analytical column.

Dosage and Reconstitution

Literature-Reported Research Doses in Rodent Models

Published rodent studies have used a wide range of doses for 5-Amino-1MQ and closely related NNMT inhibitors. The most commonly cited range is 2-50 mg/kg body weight per day, delivered by oral gavage or dissolved in drinking water. The lower end of this range (2-5 mg/kg) was used in some efficacy studies where chronic once-daily oral dosing was examined over 4-8 week periods; the higher end (20-50 mg/kg) appears in shorter-duration or acute pharmacodynamic studies. ^{[2] [10]}

Converting these literature doses to a practical capsule-based research protocol requires straightforward arithmetic. For a 25-gram mouse receiving a target literature-equivalent dose of 10 mg/kg:

• Required dose per animal = 10 mg/kg x 0.025 kg = 0.25 mg
• A single 50 mg capsule contains enough compound for 200 such administrations
• Dissolution: open one 50 mg capsule into 50 mL sterile water to produce a 1 mg/mL stock solution; 0.25 mL of this solution delivers 0.25 mg per 25-gram mouse

For a 30-gram mouse at 5 mg/kg:

• Required dose = 5 mg/kg x 0.030 kg = 0.15 mg
• Using the same 1 mg/mL stock: administer 0.15 mL per animal by gavage

For a group of 10 mice averaging 27 grams at 20 mg/kg:

• Per-animal dose = 20 mg/kg x 0.027 kg = 0.54 mg
• Total for 10 animals = 5.4 mg
• Prepare a 2 mg/mL stock solution (dissolve one 50 mg capsule in 25 mL sterile water); administer 0.27 mL per animal

Step-by-step reconstitution protocols, vehicle selection guidance, and gavage technique details are covered in our reconstitution guide. Dosage calculation methodology including body surface area conversion factors for interspecies scaling is covered in our dosage calculation guide.

Cell Culture Research Concentrations

For in vitro adipocyte or fibroblast studies replicating the published literature, concentrations of 10-100 micromolar have been used. ^[3] Converting to a practical mass-based working solution:

• Molecular weight of 5-Amino-1MQ bromide salt: 239.11 g/mol
• 50 micromolar working solution in 10 mL cell culture medium: 50 x 10^-6 mol/L x 0.01 L x 239.11 g/mol = 0.12 mg in 10 mL
• A single 50 mg capsule dissolved in 4.17 mL DMSO gives a 50 mM stock solution (DMSO should not exceed 0.1% final concentration in cell culture medium)
• Dilute 1 microliter of 50 mM DMSO stock into 999 microliters medium to produce 50 micromolar working solution with 0.1% DMSO

Note that DMSO control wells must be included in all cell culture experiments. The compound is freely water-soluble and can alternatively be prepared as a 10 mM aqueous stock to avoid DMSO carrier effects, though some researchers prefer DMSO stocks for longer-term storage stability.

Storage After Opening

Once the capsule bottle is opened, the compound should be stored under desiccating conditions at 2-8°C in the dark. The primary degradation risks are hydrolysis of the quaternary ammonium group (slow under dry, cold conditions) and oxidation of the aromatic amine at the 5-position. Prepared aqueous stock solutions should be aliquoted and stored at -20°C; freeze-thaw cycles should be limited to no more than 3-5 per aliquot.

Side Effects and Safety

Preclinical Safety Profile

The published preclinical literature does not report major toxicity signals at the research doses described above in rodent models. Rodent studies of 4-8 week duration have not reported significant changes in liver enzymes, complete blood counts, or gross pathology in treated animals at doses of 10-50 mg/kg. ^[2] However, these are typically efficacy-focused studies, not formal toxicology studies, and they are not designed with the rigor of GLP toxicology packages (which would include multiple dose cohorts, recovery groups, histopathology, and reproductive/developmental endpoints).

The absence of reported adverse findings in efficacy studies should not be interpreted as evidence of safety. The studies were generally underpowered and too short to detect sub-acute or chronic toxicity signals. Long-duration (90-day) formal toxicology data for 5-Amino-1MQ have not been published.

Theoretical Safety Considerations

Because NNMT is expressed in liver and kidney at high levels, and because the SAM methylation cycle has broad physiological functions, systemic NNMT inhibition carries theoretical risks. Excessive depletion of N-methylnicotinamide (MNAM), the product of NNMT, could theoretically affect tissues where MNAM has proposed physiological roles as a vasodilator and anti-inflammatory mediator. ^[15] Whether research doses of 5-Amino-1MQ produce MNAM depletion severe enough to affect these functions has not been formally assessed.

Immune cell function represents another area of theoretical concern. NNMT is expressed in macrophages and T cells, and its activity influences the inflammatory cytokine secretion profile. ^[13] Inhibition of NNMT in immune cells could have immunomodulatory effects that are not captured by standard metabolic endpoints in adipocyte-focused studies.

Handling Precautions for Laboratory Use

Standard laboratory personal protective equipment (PPE) applies: nitrile gloves, eye protection, and a lab coat when handling the compound in powder or dissolved form. The compound should be handled in a well-ventilated environment; fine powder inhalation should be avoided. Disposal should follow institutional chemical waste procedures for organic aromatic compounds.

How It Compares

Competitor and Related Compound Landscape

5-Amino-1MQ operates in a small but growing research space. Its closest comparators are other NNMT inhibitors, along with NAD+ precursor compounds that share overlapping downstream effects. The following table provides a structured comparison.

Mechanistic Positioning vs. NMN and NR

The comparison between 5-Amino-1MQ and NAD+ precursors like NMN or NR is nuanced and frequently misrepresented in lay commentary on these compounds. NMN and NR work by providing substrate for NAD+ synthesis directly: they enter the biosynthetic pathway upstream of NAD+ and increase the pool through mass action. 5-Amino-1MQ works by reducing the rate at which the NAD+ precursor nicotinamide is diverted into a metabolically inert methylated form.

The theoretical advantage of the 5-Amino-1MQ approach is that it addresses the underlying cause of NAD+ deficiency in NNMT-overexpressing tissues rather than compensating downstream. In a tissue with high NNMT activity, supplying excess NMN may be partially offset by elevated NNMT consuming more nicotinamide (a natural byproduct of NMN hydrolysis); inhibiting NNMT removes this drain. Whether co-administration of 5-Amino-1MQ with NAD+ precursors produces synergistic NAD+ elevation has been hypothesized but not rigorously tested in published work. ^[8]

Selectivity Advantage Over Earlier NNMT Inhibitors

Early NNMT inhibitors from the 2000s and early 2010s were often nonselective or required parenteral administration at high doses. 5-Amino-1MQ's selectivity advantage over COMT and PNMT, two structurally related SAM-dependent methyltransferases, means researchers can attribute observed phenotypes more specifically to NNMT inhibition rather than to broad SAM-cycle disruption. For rigorous mechanistic studies, pairing 5-Amino-1MQ with an NNMT-null or NNMT-knockdown genetic control remains best practice.

Where to Buy

Apollo Peptide Sciences offers this formulation at $100.00 for 60 capsules (3,000 mg total). At $0.033 per mg, this is within the typical price range for oral small-molecule research tools from established research chemical suppliers. See our full 5-Amino-1MQ product review page for details on the vendor, affiliate relationship, and purchasing process.

When comparing across vendors, the three criteria most relevant to 5-Amino-1MQ specifically are: (1) explicit statement of salt form (bromide vs. chloride vs. free base), because this directly affects molar dose calculations; (2) HPLC purity ≥98% with the chromatogram available in the CoA; (3) mass spectrometric identity confirmation. Vendors who cannot provide all three should be approached with caution regardless of price.

Open Research Questions

The published literature leaves several important questions unanswered that future research should address. These gaps are worth noting explicitly because they define the limits of what can be responsibly concluded from current data.

Does 5-Amino-1MQ Extend Lifespan in Aged Animal Models?

The compound's effects on body composition and metabolic markers in young obese mice are well documented. Whether it extends healthspan or lifespan in aged, naturally-occurring or genetic mouse models of aging is completely unstudied as of early 2026. Given that NNMT expression increases with age in multiple tissues, this is a logical next experiment for the field. The Interventions Testing Program (ITP) format, with aged C57BL/6 mice and blinded endpoint assessment, would provide a rigorous test. ^[16]

What Is the Effect on Skeletal Muscle NAD+ and Function in Aged Animals?

The muscle data discussed in the research section used young diabetic mice. Aged skeletal muscle shows well-documented NAD+ decline and mitochondrial dysfunction. Whether NNMT inhibition can improve muscle function specifically in aged animals, independent of obesity, is unexplored. Given the interest in sarcopenia as a longevity endpoint, this represents a high-value research direction.

What Are the CNS Effects, If Any?

The BBB permeability data for 5-Amino-1MQ are essentially absent from the published literature. Confirming or ruling out meaningful CNS distribution after oral administration in rodents is a necessary prerequisite for drawing any conclusions about cognitive applications. Brain microdialysis or whole-brain mass spectrometry imaging after radiolabeled compound dosing would answer this question directly.

Are There Sex Differences in Response?

Nearly all published in vivo studies have used male mice. Given that NNMT expression and activity differ between males and females in metabolic tissues, and that estrogen influences NNMT expression, sex-stratified studies are warranted. This is a systemic gap in the NNMT inhibitor field, not specific to 5-Amino-1MQ. ^[12]

What Is the Effect of Chronic Dosing on NNMT Protein Expression?

Pharmacological inhibition of enzymes sometimes triggers compensatory upregulation of the target enzyme. Whether chronic 5-Amino-1MQ administration induces NNMT upregulation at the transcriptional or translational level, potentially attenuating efficacy over time, has not been systematically examined in published studies. This is particularly relevant for researchers designing long-duration longevity studies.

Pharmacological Context, Placing NNMT in Aging Biology

The role of NNMT in aging biology is best understood through the lens of the broader metabolic reprogramming that occurs in aging tissues. As animals and humans age, NAD+ levels decline across multiple tissues, with the steepest declines observed in skeletal muscle, liver, and brain. ^[17] Simultaneously, NNMT expression increases with age in multiple tissues, including white adipose tissue and the liver, creating a self-reinforcing cycle: elevated NNMT depletes nicotinamide available for NAD+ resynthesis, further deepening the NAD+ deficit that characterizes aged tissue metabolism.

This creates a mechanistic rationale for NNMT inhibition as a longevity intervention that is distinct from simply supplementing NAD+ precursors. Reducing the rate of nicotinamide methylation in aged tissues could in principle address one of the upstream causes of age-associated NAD+ decline rather than compensating for it downstream. Whether the magnitude of the NNMT-driven drain is sufficient to meaningfully limit NAD+ availability in aged animals, relative to other causes of NAD+ decline such as reduced NAMPT expression and increased CD38-mediated NAD+ hydrolysis, remains an important quantitative question for the field.

The interaction between NNMT and the epigenome adds another dimension. The H3K4me3 changes observed with NNMT inhibition are particularly relevant because this mark is part of the epigenetic clocks that have been developed as biomarkers of biological aging. Horváth's methylation clocks and their protein analogs are thought to reflect cumulative disruption of developmental epigenetic programs; whether pharmacologically restoring SAM availability via NNMT inhibition can measurably shift clock readouts in aged tissue is a compelling experimental question. ^[11]

Researchers working at the intersection of NNMT biology, NAD+ metabolism, and epigenetic aging should be aware that these pathways intersect at multiple levels, and that interpreting results of 5-Amino-1MQ experiments requires careful use of appropriate molecular markers for each pathway independently: intracellular NAD+ quantification (enzymatic assay or mass spectrometry), SAM/SAH ratio measurement (LC-MS/MS), histone methylation profiling (ChIP-seq or mass spectrometry-based proteomics), and NNMT enzyme activity assay (fluorometric or radiometric).

The adipose tissue biology is also worth contextualizing. White adipose tissue is not simply a passive energy storage depot in the context of aging; it is an active endocrine and paracrine organ whose dysfunction contributes to systemic inflammaging. NNMT overexpression in aged WAT is accompanied by reduced mitochondrial content, increased lipid droplet size, and elevated secretion of pro-inflammatory adipokines. Each of these features has been partially reversed by NNMT inhibition in cell and animal studies, suggesting that the adipose tissue may be a primary site of therapeutic action for this compound class in aging biology. ^{[2] [7]}

FAQ